Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR132 | Q9UNW8 | 12/20 | 0.47 |
| ▸ | CMKLR2 | P46091 | 1/20 | 0.47 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 7/20 | 0.42 |
| ▸ | ITGAV | P06756 | 7/20 | 0.42 |
| ▸ | ITGB6 | P18564 | 5/20 | 0.42 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6778181 | 0.97 | GPR132 (0.45) | GPR132CMKLR2CMKLR1FOLH1ITGB3 | |
| SCHEMBL7836758 | 0.90 | NLRP3 (0.41) | GPR132CMKLR2CMKLR1ITGB3ITGAV | |
| SCHEMBL7341395 | 0.86 | MEN1 (0.42) | GPR132CMKLR2CMKLR1ITGB3ITGAV | |
| SCHEMBL6777155 | 0.86 | ITGB3 (0.48) | ITGB3ITGAVITGB6ITGB1ITGB5 | |
| SCHEMBL6782575 | 0.85 | ITGB3 (0.55) | GPR132CMKLR2CMKLR1ITGB3ITGAV | |
| SCHEMBL7834108 | 0.84 | GPR132 (0.46) | GPR132CMKLR2CMKLR1FOLH1 | |
| SCHEMBL6778020 | 0.84 | ITGB3 (0.48) | ITGB3ITGAVITGB6ITGB1ITGA2B | |
| SCHEMBL7835830 | 0.83 | ITGB3 (0.47) | ITGB3ITGAVITGB6ITGB1ITGA2B | |
| SCHEMBL6777438 | 0.83 | GPR132 (0.43) | GPR132CMKLR2CMKLR1FOLH1 | |
| SCHEMBL6774888 | 0.82 | ITGB3 (0.52) | ITGB3ITGAVITGB6ITGB1ITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0850221-B1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | SEARLE & CO (US) | 2001-07-18 | — | — | EP | claimed |
| US-6831199-B1 | In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 | G. D. SEARLE & CO. | 2004-12-14 | — | — | US | disclosed |